statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc...

4D Molecular Therapeutics, Inc. (FDMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of 4D Molecular Therapeutics, Inc. (4D Molecular or the Company) (NASDAQ: FDMT...

Peeling Back The Layers: Exploring 4D Molecular Therapeutics Through Analyst Insights

Latest Ratings for FDMT
 DateFirmActionFromTo Jan 2022SVB LeerinkInitiates Coverage OnOutperform Jan 2021B of A SecuritiesInitiates Coverage OnBuy Jan 2021Goldman SachsInitiates Coverage OnNeutral...

Strong Buy Rating for 4D Molecular Therapeutics Backed by Promising wAMD Treatment Efficacy and Safety

Analyst Tazeen Ahmad of Bank of America Securities maintained a Buy rating on 4D Molecular Therapeutics (FDMT Research Report), retaining the pri...

Shares of 4D Molecular Therapeutics Inc. (FDMT) plummeted over 35% to $17.30 by Wednesday afternoon, marking it as the top loser among U.S. stocks. Surprisingly, retail traders remain highly bullish on the stock, with Stocktwits sentiment extremely bullish (85/100) amid extremely high message volumes (95/100).<figure class="image"><img style="aspect-ratio:1308/308;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/FDMT_Sentiment_Meter_On_Jul_17_5f2f85024d.png" alt="FDMT Stocktwits Sentiment Meter On Jul 17" width="1308" height="308"><figcaption>FDMT Stocktwits Sentiment Meter On Jul 17</figcaption></figure>Initially, FDMT shares climbed following the release of encouraging mid-stage clinical study results for its 4D-150 gene therapy, aimed at treating wet age-related macular degeneration (wAMD), a chronic eye disorder that leads to blurred vision or blind spots in central vision.However, the broader market turned its focus to various downside risks, including safety concerns raised by RBC Capital. While the firm maintains 4D-150 is "best in class," it flagged a "safety blip" – one case of inflammation in a patient with a history of syphilis, Investing.com <a href="https://in.investing.com/news/stock-market-news/4d-molecular-therapeutics-tumbles-following-midstage-clinical-study-results-432SI-4316187">reported</a>. BMO Capital lowering the price target further may have added to the pressure.Despite the sell-off, retail investors on Stocktwits seem to view Wednesday’s crash as a buying opportunity. One user noted that 4D’s peers, Ocular Therapeutix Inc. (OCUL), Adverum Biotechnologies Inc (ADVM) and EyePoint Pharmaceuticals Inc. (EYPT), “are taking it on the chin today.”“Obviously, Nasdaq taking it hard today as well. &nbsp;Perhaps, just a general opinion of overvaluation and market fatigue? &nbsp;Very odd stock movement to me, I do expect it will reverse soon,” said Stocktwits user ‘<a href="https://stocktwits.com/ehschunk/message/579821570">ehschunk</a>’.<figure class="image"><img style="aspect-ratio:1318/454;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/FDMT_stocktwits_comment_Jul_17_88b7f49b68.png" alt="Stocktwits user ehschunk's post on FDMT stream" width="1318" height="454"><figcaption>Stocktwits user ehschunk's post on FDMT stream</figcaption></figure>The overall market sentiment didn’t help, as U.S. stocks pulled back from their all-time highs on Wednesday, impacted by falling chip and tech stocks, though the Dow Jones managed its sixth consecutive day of gains.FDMT shares are down over 19% year-to-date, contrasting with OCUL’s impressive 65% rise. EYPT has had an even tougher year, losing 57% so far, while ADVM has lost only 0.18%.However, FDMT’s consistent performance in beating EPS estimates for the past four quarters provides some relief and hope for a rebound among its retail investors.

Wall Street’s Top Loser Today Stays In Retail’s Good Books: Stocktwits Extremely Bullish On FDMT

Despite a 35% drop in shares, retail investors remain bullish on 4D Molecular Therapeutics

Wall Street’s Top Loser Today Remains In Retail’s Good Books

Equity

Despite a 35% drop in shares, retail investors remain bullish on 4D Molecular Therapeutics on promising clinical study results

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. (4D Molecular Therapeutics or...

Buy Rating for 4D Molecular Therapeutics Based on Promising Phase II Trial Results for 4D-150 Gene Therapy

4D Molecular Therapeutics (FDMT Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Geulah Liv...

Why Is 4D Molecular Therapeutics Stock Trading Lower On Thursday? Genetic Disease-Focused Study Data Released

4D Molecular Therapeutics shares interim data from the 4D-710 Phase 1/2 AEROW clinical trial for cystic fibrosis lung disease.
read more...

BMO Capital Markets Trims 4D Molecular Therapeutics (NASDAQ:FDMT) Target Price to $63.00

4D Molecular Therapeutics (NASDAQ:FDMT - Free Report) had its price objective reduced by BMO Capital Markets from $70.00 to $63.00 in a research note published on Monday, Benzinga reports. They...

4D Molecular Therapeutics Inc (FDMT) Chief Legal Officer Scott Bizily Sells 8,153 Shares

4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

Volume	760,871.00
52-Wk High	$36.25
52-Wk Low	$9.44

FDMT 4D Molecular Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals